Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.20)
# 3,468
Out of 4,734 analysts
107
Total ratings
31.52%
Success rate
-13.67%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Maintains: Buy | $7 → $5 | $0.36 | +1,296.65% | 7 | Jan 6, 2025 | |
| CRVO CervoMed | Maintains: Buy | $65 → $12 | $2.18 | +450.46% | 4 | Dec 11, 2024 | |
| CYBN Cybin | Maintains: Buy | $86 | $9.59 | +796.77% | 6 | Nov 19, 2024 | |
| GHRS GH Research | Maintains: Buy | $31 → $28 | $8.99 | +211.46% | 4 | Nov 18, 2024 | |
| ATAI Atai Life Sciences | Maintains: Buy | $11 | $1.50 | +633.33% | 1 | Nov 18, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $23 | $8.15 | +182.21% | 5 | Nov 14, 2024 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 | $5.22 | +168.20% | 4 | Nov 14, 2024 | |
| CLNN Clene | Maintains: Buy | $86 → $83 | $4.80 | +1,629.17% | 5 | Nov 14, 2024 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $16 → $14 | $7.18 | +94.99% | 1 | Sep 16, 2024 | |
| CMPS COMPASS Pathways | Maintains: Buy | $50 → $48 | $3.64 | +1,218.68% | 2 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $113 | $126.50 | -10.67% | 4 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 → $12 | $4.60 | +160.87% | 4 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $9.80 | +104.08% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $154 → $164 | $145.88 | +12.42% | 13 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $26 | $5.22 | +398.08% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $21 → $17 | $6.94 | +144.96% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $17.89 | +84.46% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $310 → $305 | $140.98 | +116.34% | 19 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $39.03 | +284.32% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $21.82 | - | 2 | Jan 31, 2017 |
BioXcel Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $0.36
Upside: +1,296.65%
CervoMed
Dec 11, 2024
Maintains: Buy
Price Target: $65 → $12
Current: $2.18
Upside: +450.46%
Cybin
Nov 19, 2024
Maintains: Buy
Price Target: $86
Current: $9.59
Upside: +796.77%
GH Research
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $8.99
Upside: +211.46%
Atai Life Sciences
Nov 18, 2024
Maintains: Buy
Price Target: $11
Current: $1.50
Upside: +633.33%
Zevra Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $25 → $23
Current: $8.15
Upside: +182.21%
Voyager Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $14
Current: $5.22
Upside: +168.20%
Clene
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $4.80
Upside: +1,629.17%
Mind Medicine (MindMed)
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $7.18
Upside: +94.99%
COMPASS Pathways
Aug 2, 2024
Maintains: Buy
Price Target: $50 → $48
Current: $3.64
Upside: +1,218.68%
Jun 20, 2024
Maintains: Buy
Price Target: $107 → $113
Current: $126.50
Upside: -10.67%
Jun 13, 2024
Downgrades: Hold
Price Target: $120 → $12
Current: $4.60
Upside: +160.87%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $9.80
Upside: +104.08%
May 2, 2024
Maintains: Buy
Price Target: $154 → $164
Current: $145.88
Upside: +12.42%
Apr 30, 2024
Maintains: Buy
Price Target: $36 → $26
Current: $5.22
Upside: +398.08%
Apr 26, 2024
Maintains: Hold
Price Target: $21 → $17
Current: $6.94
Upside: +144.96%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $17.89
Upside: +84.46%
Feb 20, 2024
Maintains: Buy
Price Target: $310 → $305
Current: $140.98
Upside: +116.34%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $39.03
Upside: +284.32%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $21.82
Upside: -